Luca Moscetti

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Marina Chiara Garassino, Olga Martelli, Massimo Broggini et al. · The Lancet Oncology · 2013 · 476 citations

Second-line Treatment, Oncology, Wild-type Egfr Tumours +9

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín et al. · Annals of Oncology · 2021 · 364 citations · Full text

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Daniele Santini, Sandro Barni, Salvatore Intagliata et al. · Scientific Reports · 2015 · 136 citations · Full text

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

Alessandra Fabi, Alessandra Felici, Giulio Metro et al. · Journal of Experimental & Clinical Cancer Research · 2011 · 118 citations · Full text

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)

Francesco Di Costanzo, Paolo Carlini, Laura Doni et al. · British Journal of Cancer · 2005 · 98 citations · Full text